We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dose-Related Safety and Immunogenicity of a Trivalent Baculovirus-Expressed Influenza-Virus Hemagglutinin Vaccine in Elderly Adults.
- Authors
Treanor, John J.; Gilbert M. Schiff; Couch, Robert B.; Cate, Thomas R.; Brady, Rebecca C.; Hay, C. Mhorag; Wolff, Mark; Dewei She; Cox, Manon M. J.
- Abstract
Background. Influenza-virus hemagglutinin (HA) protein expressed in insect cells by recombinant baculovirus is a candidate influenza vaccine. Methods. In a randomized, double-blind trial conducted in 399 adults ⩾65 years of age, the efficacy of trivalent inactivated influenza vaccine (TIV) licensed for intramuscular injection was compared with that of trivalent baculovirus-expressed HA vaccine administered at doses of 15 µg, 45 µg, or 135 µg of each HA. Results. Compared with TIV, baculovirus-expressed HA vaccine was safe and induced better serum antibody responses to the H3 component when administered at doses of 45 µg or 135 µg of each HA. Conclusions. Baculovirus-expressed HA is a safe and immunogenic influenza vaccine in elderly adults.
- Subjects
INFLUENZA vaccines; INFLUENZA; VIRUS diseases; IMMUNOGLOBULINS; VIRAL antibodies; INTRAMUSCULAR injections
- Publication
Journal of Infectious Diseases, 2006, Vol 193, Issue 9, p1223
- ISSN
0022-1899
- Publication type
Article
- DOI
10.1086/503050